ABSTRACT
Objective To study the effect of action‐oriented health education in the patients with permanent urinary bladder fistula .Methods From January 2012 to March 2015 ,78 patients with permanent urinary bladder fistula were randomly divided into two groups ,39 cases in the control group were given routine health education ;39 cases in the in the study group were given action‐oriented health education ,at the 12‐month follow‐up ,the QOLI and self‐care ability of the patients were used to evaluate life self‐care abilityof patient quality .Results After 12 months ,the self‐care skills ,sense of responsibility ,health knowledge score and total score of the study group were higher than those of the control group (P0 .05) .Conclusion Action‐oriented health education method has a positive effect on improving self‐care ability and quality of life ,and reducing the incidence of complications in patients with perma‐nent bladder stoma .
ABSTRACT
Objective To investigate the methylation status of the CpG island of tumor suppressor gene PCDH 8 and its clinical significance in bladder cancer tissues .Methods 79 cases of primary bladder transitional cell carcinoma and 20 cases of normal blad-der mucosa tissue were collected ,and then the promoter methylation status of PCDH8 gene was examined by methylation specific PCR (MSP) ,and correlated with clinical pathological data for statistical analysis .Results We found that no PCDH8 gene methyla-tion was detected in 20 normal bladder mucous tissues ,while PCDH8 promoter methylation was found in 44 cases of total 79 prima-ry bladder transitional cell carcinoma tissues ,the methylation rate was 55 .7% ,and the difference was statistical significant between normal bladder mucous group and bladder cancer group (P0 .05) ,the methylation rate of PCDH8 gene in tumors whose diameter more than 3 cm was 72 .7% ,while the methylation rate of PCDH8 gene in tumors whose diameter less than 3 cm was 43 .5% ,and the difference was significant(P< 0 .05) .The methylation rate of PCDH8 gene in the papillary tumor was 48 .2% ,while the methylation rate of PCDH8 gene in the unpapillary tumor was 73 .9% ,and the difference was signifi-cant(P<0 .05) .The methylation rate of PCDH8 gene in recurrent tumors was 71 .1% ,while the methylation rate of PCDH8 gene in primary tumors was 35 .3% ,and the difference was significant(P<0 .05) .The methylation rate of PCDH8 gene in tumors with G1 ,G2 phase was 43 .4% ,while the methylation rate of PCDH8 gene in tumors with G3 was 80 .8% ,and the difference was signifi-cant(P<0 .05) .The methylation rate of PCDH8 gene in the tumors with Ta T1 phase was 43 .7% ,while the methylation rate of PCDH8 gene in tumors with T2 T4 was 74 .2% ,and the difference was significant(P<0 .05) .Our result suggested that PCDH8 gene methylation was associated with tumor growth ,morphology ,recurrence ,poor differentiation and tumor invasion (P<0 .05) . Conclusion The promoter methylation of tumor suppressor gene PCDH8 is closely correlated with the occurrence and development of primary bladder transitional cell carcinoma .The promoter methylation of PCDH8 gene could be used as molecular markers of ear-ly diagnosis ,monitoring and prognosis biomarker in bladder cancer .
ABSTRACT
Objective To discuss the indication for kidney-sparing surgery (KSS) on primary urothelial carcinoma of the distal ureter.MethodsClinical data of 108 patients with primary urothelial carcinoma of the distal ureter in our hospital from 2001 to 2009 were analyzed retrospectively.There were 75 males and 33 females with mean age of 62 ( range from 42 to 85 ) years old in this study.The patients were divided into KSS group and RNU group according to the operation methods.The recurrence rate of radical nephroureterectomy (RNU) and KSS were evaluated.Results The recurrence was seen none with T,stage,1 (12.5％) with T1 stage,4 (36.4％) with T2 stage and 4 (80％) with T3 stage in KSS group.In RNU group,there was none with Ta stage,4 ( 15.4％ ) with T1 stage,10 (33.3％) with T2 stage and 7 (36.8％) with T3 stage recurred.There was no difference between patients with Ta to T2 stages in KSS and RNU group (P ＞0.05 ) on recurrence,but there was a significant difference between patients with T3 stage (P＜0.05).There was 1 (33.3％) case with G1 grade,3 (18.8％) with G2 grade and 5 (62.5％) with G3 grade recurred in KSS group,while 2 (22.2％) cases with G1 grade,9 (20％) with G2 grade and 10 (37.0％) with G3 grade recurred in RNU group.There was no difference between patients with G1 to G2 grades in KSS and RNU group (P＞0.05),but there was a significant difference between patients with G3 stage in the two groups ( P ＜ 0.05 ).Conclusion KSS seems to be safe for patients with low stage and low grade primary urothelial carcinoma of the distal ureter.
ABSTRACT
Objective To investigate the clinical feature,diagnosis,treatment and prognosis of endometriosis of the bladder.Methods A retrospective study was conducted to review the clinical data of 10 patients with bladder endometriosis.Patient's age ranged from 30 to 48 years (with mean age of 38 years).Eight cases were admitted to hospital with urinary tract irritating symptoms during the menstrual period and 6 cases with hematuria; 2 patients without any symptoms were found through examination.The course of disease was 1-36 months (with mean of18 months).Ultrasound shows with low echo,single,wide base and no significant blood flow mass whose boundaries are less clear within the bladder wall.CT reveals soft-mass protruding into the bladder.Results Eight of the 10 patients were undergone partial cystectomy.And 2 cases was treated with transurethral resection.All cases were pathologically confirmed to be bladder endometriosis.Recurrence and ectopic lesion had not be found during follow-up period from 10 to 72 months (with mean of 30 ± 5.6 mon).Conclusions Endometriosis is a common disease in females in their reproductive years,but thebladder endometriosis is rare.The initial diagnosis needs to be made combining with imaging studies.It is confirmed by cystoscopy and pathological biopsy.Surgery is the option for the treatment of bladder endometriosis.
ABSTRACT
ObjectiveTo examine the effects of temsirolimus, an inhibitor of mammalian target of rapamycin, on bladder cancer cell lines T24 and BIU-87 in vitro and in vivo for purpose of evaluating the probability of mTOR targeted therapy for bladder cancer.MethodsAfter being treated by a different concentration of temsirolimus, T24 and BIU-87 cells were tested by MTT assay for cell proliferation activity.Cell cycle and apoptosis analysis were performed with flow cytometer. Wound scratch assay was used for cell migration activity and transwell motility assay. Western blot analysis was used to test the mTOR phosphorylation. Subcutaneous inoculation of 6-week-old nude mice was performed using 1 × 106 T24 cells in 50％ matrigel for both control (n = 10) and temsirolimus (n = 10) groups. The volume of tumors was examined and then the expression of Ki-67 was detected by immunohistochemistry.ResultsTemsirolimus significantly inhibited proliferation of T24 and BIU-87 cells in a dose- and time-dependent manner. After administration of temsirolimus on T24 and BIU-87 cell lines for 24 h, the rate of wound healing in 0 nmol/L groups were (88.9 ± 14. 1 ) ％ and ( 83.6 ± 16.3)％ , which were higher than in the 5 nmol/L groups, which were (42.7 ± 11.6) ％ and ( 36.9 ± 9.7 ) ％ ( P ＜ 0.05 ). In the transwell motility assay, the number of cells in the 0 nmol/L group was 26.5 ± 5.8 and 28.2 ± 4.6, which was higher than in the 5 nmol/L group ( 19.0 ±3. 8 and 21.3 ± 5.1, respectively) (P ＜ 0. 05). When temsirolimus was administered on T24 and BIU-87 cell lines for 48 h the percentages of cells delayed in phase G0/G1 in 5 nmol/L group were ( 77.46 ±6.11)％ and (73. 39 ± 4. 94)％ respectively, and higher than in the 0 nmol/L group, which were (65.99 ±5.01 )％ 、(60.15 ±3.98)％ (P ＜0.05). There was no statistically significant difference in the apoptosis rate between the two groups (P ＞ 0.05 ). In Western blot analysis, the ratios of p-mTOR/β-actin were 0.92 ±0.09 and 1.01 ± 0.08 in 0 nmol/L group, and higher than in the 5 nmol/L group (0.47 ±0.05、0.04 ±0. 01 ) (P ＜ 0.05 ). After administration of temsirolimus for 21 days, the tumor volume in nude mice in the control group were 351.1 ± 139.9 mm3 , which was larger than 351.1 ± 139.9 mm3 in the temsirolimus group ( P ＜ 0.05 ). The positive rate of Ki-67 expression was ( 67.3 ± 8.4 ) ％ in the control group, which was higher than in the temsirolimus group ( 35.5 ± 6.7 ) ％ ( P ＜ 0.05 ).ConclusionsThis study provides in vitro and in vivo evidence that temsirolimus may inhibit the viability of bladder cancer cells and temsirolimus could be exploited as a potential therapeutic strategy in bladder cancer.